• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.

作者信息

Espinoza Magdalena, Muquith Maishara, Lim Mir, Zhu Hao, Singal Amit G, Hsiehchen David

机构信息

Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

出版信息

Gastroenterology. 2023 Jul;165(1):286-288.e4. doi: 10.1053/j.gastro.2023.02.042. Epub 2023 Mar 7.

DOI:10.1053/j.gastro.2023.02.042
PMID:36894034
Abstract
摘要

相似文献

1
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.阿替利珠单抗联合贝伐单抗治疗肝细胞癌后的疾病病因及预后：IMbrave150事后分析
Gastroenterology. 2023 Jul;165(1):286-288.e4. doi: 10.1053/j.gastro.2023.02.042. Epub 2023 Mar 7.
2
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
3
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
4
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
5
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的真实世界数据：符合 IMbrave150 试验纳入标准对预后的影响如何？
Target Oncol. 2023 Mar;18(2):221-233. doi: 10.1007/s11523-023-00953-x. Epub 2023 Mar 15.
6
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.经动脉放射性栓塞与阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌：生活质量恶化时间的匹配调整间接比较。
Adv Ther. 2022 May;39(5):2035-2051. doi: 10.1007/s12325-022-02099-0. Epub 2022 Mar 12.
7
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗在不可切除肝细胞癌序贯治疗中的作用。
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
8
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.美国食品和药物管理局批准概要：阿替利珠单抗联合贝伐珠单抗用于治疗不可切除或转移性肝细胞癌患者。
Clin Cancer Res. 2021 Apr 1;27(7):1836-1841. doi: 10.1158/1078-0432.CCR-20-3407. Epub 2020 Nov 2.
9
A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma.一例使用阿替利珠单抗治疗晚期肝细胞癌后发生的横贯性脊髓炎病例。
Korean J Gastroenterol. 2023 Jul 25;82(1):35-39. doi: 10.4166/kjg.2023.054.
10
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.

引用本文的文献

1
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.阿替利珠单抗联合贝伐单抗治疗肝细胞癌的真实世界疗效：法国前瞻性CHIEF队列研究
Liver Int. 2025 Oct;45(10):e70337. doi: 10.1111/liv.70337.
2
Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.代谢功能障碍相关脂肪性肝病与肝细胞癌：临床实践中的挑战
Clin Exp Hepatol. 2025 Jun;11(2):105-112. doi: 10.5114/ceh.2025.151618. Epub 2025 Jun 9.
3
Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study.
肝细胞癌切除术后复发高危患者辅助免疫检查点抑制剂的治疗持续时间：一项前瞻性、多中心队列研究
Liver Cancer. 2024 Dec 4;14(4):378-390. doi: 10.1159/000542954. eCollection 2025 Aug.
4
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab.肝细胞癌的病因可能会影响阿替利珠单抗联合贝伐单抗治疗下的进展模式。
Liver Cancer. 2025 May 26:1-14. doi: 10.1159/000545494.
5
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的真实世界经验：一项多中心研究
Cancers (Basel). 2025 May 29;17(11):1814. doi: 10.3390/cancers17111814.
6
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌中动脉FOLFOX与阿替利珠单抗-贝伐单抗的匹配调整间接比较
Liver Cancer. 2025 Apr 22:1-18. doi: 10.1159/000545891.
7
Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network.阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌患者：来自美国社区肿瘤网络的真实世界经验
J Hepatocell Carcinoma. 2025 Apr 18;12:791-804. doi: 10.2147/JHC.S492881. eCollection 2025.
8
Advances in Immunotherapy in Hepatocellular Carcinoma.肝细胞癌免疫治疗的进展
Int J Mol Sci. 2025 Feb 24;26(5):1936. doi: 10.3390/ijms26051936.
9
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.潜在肝脏疾病对接受免疫检查点抑制剂治疗的不可切除肝细胞癌的影响。
BJC Rep. 2024 Jan 29;2(1):8. doi: 10.1038/s44276-024-00038-w.
10
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.接受阿替利珠单抗联合贝伐单抗与索拉非尼或乐伐替尼作为一线治疗的不可切除肝细胞癌真实世界患者的总生存期：来自美国退伍军人健康管理局数据库的研究结果
Cancers (Basel). 2024 Oct 17;16(20):3508. doi: 10.3390/cancers16203508.